NVST
Envista Holdings CorpPrice & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Core growth in Equipment and Consumables segment non-GAAP | 11.5% | Q1 2026 | — |
| Core growth in Specialty Products & Technologies segment non-GAAP | 8.4% | Q1 2026 | — |
| Core sales growth non-GAAP | 9.5% | Q1 2026 | — |
|
|
|||
| Free cash flow non-GAAP | -$16M | Q1 2026 | — |
|
|
|||
| Shares repurchased | 1.6M | Q1 2026 | — |
| adjusted EBITDA margin non-GAAP | 14% | Q1 2026 call | — |
| adjusted EBITDA margin expansion non-GAAP | 120 | Q1 2026 call | — |
| adjusted EPS non-GAAP | $0.36 | Q1 2026 call | — |
| adjusted EPS growth non-GAAP | 50% | Q1 2026 call | — |
| adjusted gross margin non-GAAP | 55.8% | Q1 2026 call | — |
| core revenue growth | 9.5% | Q1 2026 call | — |
| images processed annually | 500M | Q1 2026 call | — |
| non-GAAP tax rate non-GAAP | 26.1% | Q1 2026 call | — |
| share repurchase program incremental authorization | $300M | Q1 2026 call | — |
| underserved patients supported through Envista Smile project | 4,000 | Q1 2026 call | — |
| Free cash conversion non-GAAP | 114% | FY 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVST
this stock
Envista Holdings Corp
|
$4.22B | +19.3% | -0.1% | 63.2 | 6.0% |
|
ISRG
Intuitive Surgical Inc
|
$144.07B | -28.2% | +20.5% | 49.4 | 2.1% |
|
MDLN
Medline Inc.
|
$53.91B | -2.3% | +11.5% | — | 2.8% |
|
BDX
Becton Dickinson & Co
|
$41.87B | +0.9% | +8.2% | 57.7 | 4.1% |
|
ALC
Alcon Inc
|
$33.07B | -14.0% | +10.5% | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVST | -6.2% | +7.7% | +4.9% | -1.7% | +19.4% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -7.6% | +3.6% | -4.1% | -2.8% | +8.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.